Law Firm Probes Celldex Therapeutics Over Possible Board Breaches
Purcell & Lefkowitz LLP is investigating Celldex Therapeutics directors for potential fiduciary duty violations on behalf of shareholders.
New York-based law firm Purcell & Lefkowitz LLP has launched an investigation into Celldex Therapeutics, Inc. (NASDAQ: CLDX), examining whether the biopharmaceutical company's board of directors breached their fiduciary duties to shareholders, the firm announced October 12, 2026.
The probe targets the conduct of Celldex's directors and centers on whether those executives fulfilled their legal obligations to act in the best interests of the company's investors. Shareholder investigations of this kind typically precede potential litigation and are designed to determine whether grounds exist for a lawsuit alleging corporate mismanagement or self-dealing.
Read more Berger Montague Probes Webull After Class Action Filed →
Celldex Therapeutics, traded on the Nasdaq exchange under the ticker CLDX, is a clinical-stage biopharmaceutical firm. Shareholder-rights investigations by plaintiff law firms have become a common mechanism for holding corporate boards accountable when investors believe decisions may have harmed share value or violated governance standards.
No lawsuit has been publicly announced at this stage. Shareholders with relevant information or those who wish to learn more about their legal rights are typically encouraged to contact the investigating firm directly. The outcome of such investigations can range from no further action to formal class-action or derivative litigation.
Continue reading at All Financial Services & Investing.
